RARE DISEASES CLINICAL RESEARCH NETWORK
Rare Organic Acidemias Research Consortium |  |
A collaborative network for advancing research in organic acidemias, a group of inherited metabolic disorders where the body cannot properly break down certain proteins and fats, leading to a buildup of organic acids. | |
Principal Investigators
Baylor College of Medicine
THE
NUMBERS
What was your consortium's most significant achievement from the past year?
V. Reid Sutton, MD, Principal Investigator, ROAR: ROAR's most significant achievement in its first year of RDCRN Cycle 5 was establishing the infrastructure needed to support multicenter research in rare organic acidemias. Through the ROAR Kickoff Meeting, investigators, patient advocacy partners, NIH representatives, the DMCC, and External Advisory Committee members aligned on study priorities, data standards, governance, and long-term scientific goals. ROAR subsequently finalized governance structures, executed data-sharing agreements, initiated REDCap development, obtained NIH approval for its flagship natural history study (ROAR9201), and developed Data and Biospecimen Use and Publication Policies. Together, these efforts created a sustainable framework for collaborative research, data sharing, and future biospecimen resources.
What did this achievement accomplish?
Dr. Sutton: These efforts transformed ROAR from a newly funded consortium into an operational, multicenter research network with a shared scientific vision and standardized processes for data and biospecimen sharing. The consortium established centralized stewardship through Baylor College of Medicine, Executive Committee oversight of data and biospecimen requests, publication governance procedures, and mechanisms for sharing de-identified data consistent with NIH and RDCRN policies. ROAR also created the framework for a longitudinal biorepository linked to clinical outcomes data. In addition, ROAR partnered with the Brittle Bone Disorders Consortium (BBDC) to develop a shared Career Enhancement Program that expanded mentorship, career development opportunities, and cross-consortium collaboration for early-career investigators.
How will this impact the rare disease community?
Dr. Sutton: ROAR9201 will create one of the largest prospective longitudinal clinical and biospecimen resources for rare organic acidemias in North America. The study will enroll approximately 300 participants across five institutions and collect standardized clinical data and optional biospecimens over multiple years. Patient advocacy organizations have been engaged since study inception, helping shape recruitment, dissemination, and family-centered research priorities. By implementing harmonized data standards, FAIR data principles, and transparent resource-sharing policies, ROAR is creating a durable platform for studies of disease progression, biomarkers, genotype-phenotype relationships, treatment outcomes, therapeutic development, and clinical trial readiness.
How will this advance the goals of your consortium and/or the RDCRN at large?
Dr. Sutton: This achievement directly advances RDCRN priorities by creating durable, shareable research resources that support collaboration, data harmonization, and long-term scientific reuse. ROAR established formal procedures for concept review, data access, biospecimen utilization, publication review, authorship attribution, and transfer of data to NIH-designated repositories. The consortium also collaborated with BBDC to develop a shared Career Enhancement Program that promotes mentorship, investigator development, and cross-consortium learning. Combined with ROAR9201 and the planned longitudinal biorepository, these efforts create a future-ready research platform that will accelerate discovery, support biomarker validation and therapeutic development, strengthen clinical trial readiness, and build the next generation of rare disease investigators.